Letter to the Editor
Leukemia (2006) 20, 142–143. doi:10.1038/sj.leu.2404029; published online 10 November 2005
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia
M Bocchia1, E Abruzzese2, F Forconi1, M Ippoliti1, M M Trawinska2, M T Pirrotta1, D Raspadori1, M Tozzi1, A Gozzetti1 and F Lauria1
- 1Department of Hematology, University of Siena, Siena, Italy
- 2Department of Hematology, Roma 'Tor Vergata' University, Roma, Italy. E-mail: bocchia@unisi.it
Top of page
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Leukemia Letter
Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells
Leukemia Letter
Leukemia Letter
Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia
Leukemia Original Article
